EUCTR2020-001527-14-NL进行中（未招募）1 期
COVID-19: addition of azithromycin to chloroquine treatment - CO VOR IT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Erasmus MC
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Proven diagnosis of COVID-19 by positive PCR in any specimen < 48 hours prior to randomization.
- •Age = 18 year
- •Hospitalized patients with illness of any duration, and SpO2 = 94% on room air
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Severe hypoxemic respiratory failure expected to die < 72 hours after admission
- •ICU admission < 72 hours
- •Allergy for chloroquine or azithromycin
- •QT-prolongation: pre-existent: QTc males >450ms, QTc females > 470ms at day 1 and at day 2
- •Myasthenia gravis
研究者
相似试验
暂停
3 期
COVID-19: addition of azithromycin to chloroquine treatmentCOVID-19 infection10024970NL-OMON49080Erasmus MC, Universitair Medisch Centrum Rotterdam60
进行中（未招募）
1 期
Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19) - Randomised Controlled Trial, phase IIIEUCTR2020-001456-18-CZadacní fond Donatio intensivistam240
尚未招募
3 期
Efficay of two hydroxychloroquine based drug combination regimens in comparison to standard of care in The Treatment of Hospitalized COVID-19 PatientsCOVID 19PACTR202010519682638ational Institute for Pharmaceutical Research and Development NIPRD210
已完成
不适用
Anti Infective Agents Impact in COVID-19 PneumoniaCOVIDPneumonia, ViralNCT04453501Centre d'Investigation Clinique et Technologique 805132
已完成
2 期
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South AmericaMalaria, FalciparumNCT00084227Pfizer244